Back
Related Posts
XENOTHERA continues to advance cancer treatment with XON11, an innovative antibody targeting pancreatic cancer
April, 2026. In collaboration with CR2TI in Nantes (Center for Research in Transplantation and Translational Immunology), XENOTHERA presented the anti-cancer activity of XON11, its innovative treatment targeting pancreatic cancer, derived from its GH-pAbs technology platform (glyco-humanized polyclonal antibodies), at the Cancer Research Center of Marseille Congress.
Read MoreXENOTHERA strengthens its position in oncology and announces several clinical advances and scientific publications
October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications
Read MoreXENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody
June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone
Read More